Literature DB >> 24467493

Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.

Xingang Li1, Zhigang Zhao, Liang Li, Tianyan Zhou, Wei Lu.   

Abstract

Modeling and simulation are aimed at achieving information about the behaviors of the drugs without the actual measurements and determination. The purpose of this study was to characterize the in vivo behavior of exenatide microspheres using model-based methods. Exenatide is a glucagon-like peptide-1 agonist medication, belonging to the group of incretin mimetics, approved for the treatment of diabetes mellitus type 2. An oil-in-water solvent evaporation method was used to prepare the exenatide microspheres and their physicochemical features were investigated. After subcutaneous injection of exenatide microspheres to streptozotocin-induced diabetic rats, the exenatide concentrations increased and kept increasing and the blood glucose decreased in all diabetic rats. The in vivo release behavior of exenatide from microspheres was described by a transit compartment model. Based on the transit compartment model, the simulation method was proposed for the description of in vivo release. The in vitro and in vivo correlation (IVIVC) was established by the model-based simulation (R(2) = 0.903) and deconvolution (R(2) = 0.922) methods successfully. Using a transit compartment model to characterize the in vivo exenatide release from microspheres is an acceptable approach, and the IVIVC can be estimated reliably with the model-based simulation method.

Entities:  

Keywords:  Exenatide; in vitro and in vivo correlation; microspheres; pharmacokinetics; transit compartment model

Mesh:

Substances:

Year:  2014        PMID: 24467493     DOI: 10.3109/10717544.2013.871760

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  8 in total

Review 1.  In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?

Authors:  Jie Shen; Diane J Burgess
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

2.  Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment.

Authors:  Han Liu; Suohui Zhang; Zequan Zhou; Mengzhen Xing; Yunhua Gao
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

3.  Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis.

Authors:  João C Ribeiro; Ana D Martins; Ivana Jarak; Rui A Carvalho; Marco G Alves; Pedro F Oliveira
Journal:  Biomedicines       Date:  2022-05-11

4.  In Vitro and In Vivo Correlation of Bone Morphogenetic Protein-2 Release Profiles from Complex Delivery Vehicles.

Authors:  Maurits G L Olthof; Marianna A Tryfonidou; Mahrokh Dadsetan; Wouter J A Dhert; Michael J Yaszemski; Diederik H R Kempen; Lichun Lu
Journal:  Tissue Eng Part C Methods       Date:  2018-07       Impact factor: 3.056

5.  Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method.

Authors:  Heejun Park; Dong-Hyun Ha; Eun-Sol Ha; Jeong-Soo Kim; Min-Soo Kim; Sung-Joo Hwang
Journal:  Pharmaceutics       Date:  2019-11-24       Impact factor: 6.321

6.  Metformin hydrochloride entrapment in sorbitan monostearate for intestinal permeability enhancement and pharmacodynamics.

Authors:  Omar Y Mady; Adam A Al-Shoubki; Ahmed A Donia; Waseem Qasim
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

7.  Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation.

Authors:  Dong-Seok Lee; Dong Wook Kang; Go-Wun Choi; Han-Gon Choi; Hea-Young Cho
Journal:  Pharmaceutics       Date:  2020-01-02       Impact factor: 6.321

8.  Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.

Authors:  Junqiu Zhai; Zhanlun Ou; Liuting Zhong; Yu-E Wang; Li-Ping Cao; Shixia Guan
Journal:  Drug Deliv       Date:  2020-11-18       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.